Translating a complex clinical story for the whole register with Starpharma.

Few equity stories are harder to tell than a clinical biotech's. Milestones like FDA alignment and preclinical data matter enormously, but they arrive in the language of oncology and regulatory strategy, not the language most retail shareholders read every day. Starpharma needed an efficient way to communicate a highly technical story to its whole register, not just the top 20, and to see who was actually engaging.

Starpharma distributes every ASX announcement directly to its register and amplifies it with synchronised email, rather than repeating the same updates one investor at a time. Technical newsflow is paired with accessible video — CEO updates through to explainer content — held in one central video library, and an automated monthly report shows shareholder growth, register movements, engagement, and top buyers and sellers.

Since moving to InvestorHub in September 2025, Starpharma has run a milestone-packed year through one hub: FDA alignment on the DEP® HER2 clinical path, positive DEP® HER2-Lu preclinical data, and a first-in-human Phase 1 study on track for H2 2026. Its lean, in-house IR team communicates every announcement to the full register and keeps an engaged shareholder base that continues to grow and outpaces similar market-cap peers. As CEO Cheryl Maley puts it: “For a company with a story as technical as ours, being able to reach and engage our whole register, not just our largest holders, has become a core part of how we build long-term shareholder support.”